Drug SafetyThe study demonstrated an acceptable safety profile of co-administration of the two medications, and no relevant PK interactions were observed between the two drugs.

PartnershipsBoehringer Ingelheim owns 18% of the company after taking a stake in Minerva, so it is suspected they will support the further development of roluperidone.

Bears Say

Financial HealthThe company reported cash at $21.5M by the end of 2024, compared with the cash position at $41M by the end of 2023; the company should have approximately one-year cash runway.

Regulatory ChallengesThe company's efforts to avoid needing to do another Phase 3 study appears to be counterproductive since the Agency has made it clear on the need for at least one additional study to support the safety and effectiveness of roluperidone.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

6.80%

Insiders

21.21% Mutual Funds

0.30% Other Institutional Investors

68.12% Public Companies and

Individual Investors

Detailed Ownership Overview >

NERV FAQ

What was Minerva Neurosciences’s price range in the past 12 months?

Minerva Neurosciences lowest stock price was $1.15 and its highest was $3.30 in the past 12 months.

What is Minerva Neurosciences’s market cap?

Minerva Neurosciences’s market cap is $13.85M.

When is Minerva Neurosciences’s upcoming earnings report date?

Minerva Neurosciences’s upcoming earnings report date is Aug 12, 2025 which is in 19 days.

How were Minerva Neurosciences’s earnings last quarter?

Minerva Neurosciences released its earnings results on May 13, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$1.07 by $0.57.

Is Minerva Neurosciences overvalued?

According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Minerva Neurosciences pay dividends?

Minerva Neurosciences does not currently pay dividends.

What is Minerva Neurosciences’s EPS estimate?

Minerva Neurosciences’s EPS estimate is -0.9.

How many shares outstanding does Minerva Neurosciences have?

Minerva Neurosciences has 6,993,406 shares outstanding.

What happened to Minerva Neurosciences’s price movement after its last earnings report?

Minerva Neurosciences reported an EPS of -$0.5 in its last earnings report, beating expectations of -$1.07. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Minerva Neurosciences?

Currently, no hedge funds are holding shares in NERV

Company Description

Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.